Seeking Alpha

More on Quest Diagnostics (DGX) Q2: Sells rights to royalties of "non-core" experimental cancer...

More on Quest Diagnostics (DGX) Q2: Sells rights to royalties of "non-core" experimental cancer drug Ibrutinib to Royalty Pharma for $485M, with resulting cash proceeds $300M. Ibrutinib is developed by Pharmacyclics (PCYC) and Johnson & Johnson (JNJ). (PR)

Check out Seeking Alpha’s new Earnings Center »

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs